A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection

NCT03787186 | Completed Phase 1

• 1 other identifier: GLPG1690-CL-107
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

The sponsor wants to investigate how well the test medicine is taken up by the body when given orally (by mouth) as a tablet or capsule and as a solution for infusion (into a vein). The capsule and the solution will be radiolabelled. 'Radiolabelled' means that the test medicine has a radioactive component which helps us to track where the test medicine is in the body.

Conditions

Healthy

Outcome Measures

Primary Outcomes (6)

• Change of total radioactivity excreted in urine and feces combined (µg) from baseline at Day 10 (Part 2)

  To assess the mass balance using \[14C\]-GLPG1690.

  From Day 1 pre-dose up to Day 10

• Maximum observed plasma concentration (Cmax) of total radioactivity (Part 2).

  To assess the pharmacokinetics (PK) of GLPG1690 and its main metabolites in plasma

  From Day 1 pre-dose up to Day 10

• Maximum observed plasma concentration (Cmax) of GLPG1690 (Part 2).

  To assess the pharmacokinetics (PK) of GLPG1690 and its main metabolites in plasma

  From Day 1 pre-dose up to Day 10

• Area under the plasma concentration-time curve (AUC) of total radioactivity (Part 2).

  To assess the PK of GLPG1690 and its main metabolites in plasma

  From Day 1 pre-dose up to Day 10

• Area under the plasma concentration-time curve (AUC) of GLPG1690 (Part 2).

  To assess the PK of GLPG1690 and its main metabolites in plasma

  From Day 1 pre-dose up to Day 10

• Change in amount of [14C] GLPG1690 excreted in urine and feces combined (µg) from baseline at Day 7 (Part 2).

  To better characterize the elimination pathways and metabolite profile of GLPG1690

  From Day 1 pre-dose up to Day 7

Secondary Outcomes (5)

• Intravenous (IV) maximum observed plasma concentration (Cmax) of [14C]-GLPG1690 microtracer (MT) (Part 1).

  From Day 1 pre-dose up to Day 4

• Intravenous (IV) maximum observed plasma concentration (Cmax) of total radioactivity (Part 1).

  From Day 1 pre-dose up to Day 4

• IV Area under the plasma concentration-time curve (AUC) of [14C]-GLPG1690 microtracer (MT) (Part 1).

  From Day 1 pre-dose up to Day 4

• IV Area under the plasma concentration-time curve (AUC) of total radioactivity(Part 1).

  From Day 1 pre-dose up to Day 4

• Safety and tolerability of GLPG1690, assessed by the number of subjects with adverse events (AEs) (Part 1 and Part 2).

  From screening through study completion, an average of 2 months

Study Arms (2)

GLPG1690 oral and IV

EXPERIMENTAL

GLPG1690 film-coated tablets followed by \[14C\]-GLPG1690 solution for infusion

Drug: GLPG1690 film-coated tablets; Drug: [14C]-GLPG1690 solution for infusion

[14C]-GLPG1690 capsules

EXPERIMENTAL

\[14C\]-GLPG1690 capsules

Drug: [14C]-GLPG1690 capsules

Interventions

GLPG1690 film-coated tablets DRUG

a single oral dose of GLPG1690

GLPG1690 oral and IV

[14C]-GLPG1690 solution for infusion DRUG

a 15-minute IV infusion \[14C\]-GLPG1690

GLPG1690 oral and IV

[14C]-GLPG1690 capsules DRUG

single oral dose of \[14C\]-GLPG1690

[14C]-GLPG1690 capsules

Eligibility Criteria

• Age: 30 Years - 64 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able and willing to comply with the clinical study protocol (CSP) requirements and sign the informed consent form (ICF) as approved by the Independent Ethics Committee (IEC), before any screening evaluations.
• Male subjects between 30 to 64 years of age (extremes included), on the date of signing the ICF.
• A body mass index between 18 to 32 kg/m2 (extremes included).
• Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and fasting clinical laboratory safety tests, and not having had any clinically significant illness in the 3 months before first investigational medicinal product (IMP) administration.
• Having a regular and (at least) daily defecation pattern.
• Able and willing to comply with restrictions on prior and concomitant medication as described in the protocol.
• Nonsmoker, defined as an individual who has abstained from smoking (or the use of e-cigarettes or nicotine containing products) from at least 2 months before screening. Having a breath carbon monoxide reading of ≤10 parts per million.
• Negative urine drug screen (e.g. amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, tricyclic antidepressants) and alcohol breath test.
• Male subjects with female partners of childbearing potential willing to comply with the contraceptive methods described in the protocol from the time of the first IMP administration, during the clinical study, and for at least 90 days after the last IMP administration.

You may not qualify if:

• Known hypersensitivity to IMP ingredients or history of a significant allergic reaction to IMP ingredients as determined by the investigator, such as anaphylaxis requiring hospitalization, and/or known sensitivity to IMP or the excipients (e.g. lactose). Hayfever is allowed unless active.
• Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) antibody, or history of hepatitis from any cause with the exception of a history of hepatitis A infection at least 12 weeks before first IMP administration.
• History of or a current immunosuppressive condition (e.g. human immunodeficiency virus \[HIV\] infection).
• History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated and with no evidence of recurrence).
• Hemoglobin level below the lower limit of normal (LLN; 13.0 g/dL). Retesting is allowed once.
• Significant blood loss (including blood donation \[\>450 mL\]) or transfusion of any blood product within 12 weeks before screening.
• Active drug abuse (per investigator judgment) or alcohol abuse (more than three glasses of wine, beer, or equivalent/day) within 3 months before first IMP administration.
• Concurrent participation or participation in a drug, drug/device or biologic investigational research study within 12 weeks or 5 half-lives of the drug, whichever is longer, before first IMP administration.
• Radiation exposure, including that from the present study, excluding background radiation but including diagnostic Xrays and other medical exposures, exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, can participate in the study.

Sponsors & Collaborators

• Galapagos NV: lead

Study Sites (1)

Quotient Sciences Limited

Ruddington, NG11 6JS, United Kingdom

Location

Study Officials

• Christopher Brearley, BM. MRCP

  Galapagos NV

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 17, 2018
• First Posted: December 26, 2018
• Study Start: November 9, 2018
• Primary Completion: January 17, 2019
• Study Completion: January 17, 2019
• Last Updated: February 15, 2019

Record last verified: 2019-02

Locations

GB (1)